Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
RNA is finding a new role in medicine. Once thought to exist only within cells, the molecule is now known to travel all over the body, under the protection of ‘extracellular vesicles’. Scientists are studying the potential of extracellular RNA for detecting and treating disease.
RNA is now known to travel outside cells to tissues around the body. Researchers are working out whether they can exploit this extracellular RNA to detect and treat disease.
A serendipitous finding led Juan Pablo Tosar to uncover the protein-making machinery outside cells — a discovery that has scientists rethinking fundamental assumptions.
Vesicles secreted by stem cells might give clinicians a safer and simpler alternative to cell therapy, but researchers are still grappling with how best to prepare and study these tiny particles.
Some studies have suggested that plants and fungi exchange RNA through extracellular vesicles. This has led some scientists to develop crop sprays that contain RNA.
Tissue fixation with formaldehyde and a water-soluble carbodiimide crosslinker (EDC) leads to retention of extracellular vesicles within tissues and allows for reliable extracellular vesicle imaging for semiquantitative imaging applications.
Large quantities of extracellular vesicles produced via cellular nanoporation, and loaded with endogenously transcribed therapeutic mRNAs and targeting peptides, boost therapeutic outcomes in vivo.
Leidal et al. show that the LC3-conjugation pathway, which is part of the autophagy machinery, controls extracellular vesicle cargo loading and secretion of RNA-binding proteins.
Extracellular vesicles (EV) facilitate intercellular transfer of biological material including RNA, but the regulatory mechanisms for their formation and transfer are incompletely known. Here the authors develop a CRISPR-based reporting system to detect the transfer of guide RNAs and identify genes not previously linked to EV-mediated RNA delivery.
Exosomes improve the delivery of siRNA to mutant KRAS in the pancreatic tumours and bypass immune clearance better than artificial liposomes, probably owing to enhanced macropinocytocis and presence of CD47 on exosomes, respectively.
Integrating silencing RNA into the backbone of a microRNA that is highly enriched in small extracellular vesicles reduces the therapeutic dose of the silencing RNA.